{"schema_version":"secwatch.filing_event.v1","accession":"0001387131-23-009623","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.904407+00:00","generated_at":"2026-06-11T17:06:12.888963+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tonix Pharma Q2 2023 net loss $28.4M; completes acquisition of two migraine products","bullets":["Net loss $28.4M ($2.68/sh) vs $27.4M ($7.64/sh) in Q2 2022; R&D expense rose to $22.0M from $16.6M.","Cash & equivalents $25.6M at June 30, down from $120.2M at Dec 31, 2022; raised $7.0M in Aug 2023 offering.","Closed acquisition of Zembrace SymTouch and Tosymra from Upsher-Smith for $15M plus $10M inventory; trailing sales ~$30M.","Enrolled four CNS trials: RESILIENT fibromyalgia (Q4 topline), PREVAIL Long COVID (Q3), PREVENTION chronic migraine (Q4), UPLIFT MDD (Q4)."],"urls":{"canonical":"https://secwatch.observer/filing/0001387131-23-009623","json":"https://secwatch.observer/filing/0001387131-23-009623.json","markdown":"https://secwatch.observer/filing/0001387131-23-009623.md","text":"https://secwatch.observer/filing/0001387131-23-009623.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000138713123009623/0001387131-23-009623-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000138713123009623/tnxp_8k-081023.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:06:12.888963+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5554d82383a00dfda34e887a7930e5b38334a05e","claim":"Tonix Pharmaceuticals Holding Corp. reported financial results for second quarter ended June 30, 2023.","evidence_excerpt":"Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1430306/000138713123009623/0001387131-23-009623-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}